Jinan Zhuocheng Bio-Tech Co., Ltd.

Recently, the Intermediate People’s Court of Huaihua City, Hunan Province, issued a public notice announcing the bankruptcy application of Sinopharm Holding Huaihua Co., Ltd. This marks the second Sinopharm Holding subsidiary in Hunan to enter judicial bankruptcy proceedings, following Sinopharm Holding Hunan Retail Chain Co., Ltd.

The simultaneous withdrawal of a regional pharmaceutical distribution platform and a retail platform not only highlights the operational difficulties faced by individual companies but also reflects the broader transformation currently taking place across China’s pharmaceutical distribution sector.

Sinopharm Holding Huaihua Enters Bankruptcy Liquidation Amid Debt Pressure

According to the announcement from the Huaihua Intermediate People’s Court, the court accepted the bankruptcy liquidation case of Sinopharm Holding Huaihua Co., Ltd. on April 15, 2026, and appointed Hunan Huaizhen Law Firm as the bankruptcy administrator on May 26.

The announcement stated that all creditors must submit written claims to the administrator before September 1, 2026. The first creditors’ meeting is scheduled to be held on September 15, 2026.

The bankruptcy application was filed by Sinopharm Holding Changsha Co., Ltd., the company’s upstream shareholder and creditor. The reason for the application was that Sinopharm Holding Huaihua was unable to repay matured debts and its assets were insufficient to cover total liabilities, meeting the legal requirements for bankruptcy liquidation.

As a regional pharmaceutical distribution company, Sinopharm Holding Huaihua previously relied mainly on drug distribution services for hospitals and primary healthcare institutions. However, amid shrinking distribution margins, rising financial pressure and intensified industry competition, regional pharmaceutical distributors have faced increasing operational challenges. The company eventually entered bankruptcy proceedings due to liquidity difficulties.

Sinopharm Holding Hunan Retail Chain Withdraws From the Retail Market

Compared with the debt-driven bankruptcy of Sinopharm Holding Huaihua, the withdrawal of Sinopharm Holding Hunan Retail Chain Co., Ltd. represents a strategic adjustment in the pharmaceutical retail sector.

On December 16, 2025, the Kaifu District People’s Court in Changsha accepted the company’s bankruptcy liquidation application.

Established in 2018 with registered capital of RMB 10 million, Sinopharm Holding Hunan Retail Chain was once positioned as Sinopharm Holding’s provincial retail platform in Hunan. At its peak, the company operated 38 directly owned stores and 13 controlled retail subsidiaries.

The company attempted to build a province-wide prescription drug retail network through a “platform-based and streamlined” operating model, focusing on hospital pharmacies, hospital-adjacent pharmacies and community-based pharmaceutical services.

However, the expected growth of prescription outflow from hospitals progressed slower than anticipated, while competition in the retail pharmacy market continued to intensify. As a result, the company remained loss-making after establishment. Most stores were closed in 2023, and all offline retail operations ceased in 2025.

By the end of July 2025, the company’s assets had fallen to approximately RMB 4.47 million, while total liabilities exceeded RMB 55.9 million, resulting in an asset-liability ratio of more than 1,200%. The company had effectively lost its ability to continue operations.

Currently, the liquidation process is underway, with most affiliated stores and branches having completed closure and deregistration procedures.

Sinopharm’s Regional Restructuring Reflects Broader Industry Transformation

Industry analysts believe that the bankruptcy proceedings involving the two Hunan subsidiaries are not isolated events but part of a broader restructuring trend across China’s pharmaceutical distribution industry.

In recent years, policies such as the “Two-Invoice System,” centralized drug procurement, healthcare cost control measures and changes in retail pharmacy models have significantly reshaped the pharmaceutical supply chain. Traditional distributors that relied primarily on scale expansion are facing increasing pressure from declining margins, higher capital requirements and intensified competition.

Regional pharmaceutical wholesalers are being challenged by lower distribution profits and increased working capital requirements, while retail pharmacies face difficulties related to prescription conversion, high operating costs and changing consumer behavior.

Against this backdrop, Sinopharm Holding has been accelerating business optimization by reducing inefficient, loss-making and non-core assets, while focusing resources on higher-value segments, including hospital SPD services, high-end pharmaceutical distribution, pharmaceutical manufacturing and integrated supply chain solutions.

The restructuring of Sinopharm’s Hunan subsidiaries reflects a larger shift within China’s pharmaceutical circulation industry—from scale-driven expansion toward value-oriented growth. In the future, pharmaceutical distribution companies will increasingly compete on operational efficiency, professional service capabilities, digital transformation and supply chain integration.

Companies lacking differentiated advantages may face further consolidation pressure, while platform enterprises with strong supply chain capabilities, digital infrastructure and healthcare service networks are expected to gain greater opportunities during the next phase of industry restructuring.